Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1557 Results for "
ADC Linker
" in MedChemExpress (MCE) Product Catalog:
Products (1557)
1557 Results for "ADC Linker" in MCE Product Catalog:
Cat. No.: HY-141599
CAS No.: 1853239-04-9
Synonyms: ADCT 301
Research Areas:
Cat. No.: HY-151709A
CAS No.: 2737202-65-0
Target:
Research Areas:
N3-L-Cit-OH DCHA is a click chemistry reagent containing an azide group. N3-L-Cit-OH DCHA can be used to construct peptidomimetic ADC linkers using Click-chemistry . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
Cat. No.: HY-156230
CAS No.: 2855124-74-0
Target:
Research Areas:
Man-GIcNAc-oxazoline is a disaccharide oxazoline based on Manβ1,4GlcNAc. Man-GIcNAc-oxazoline serves as a donor substrate for transglycosylation in endoglycosidase-mediated antibody Fc glycan remodeling. Man-GIcNAc-oxazoline can be modified with azides, PEG-linked azides, fluorescent probes, biotin groups, ligands or prodrugs. Man-GIcNAc-oxazoline can be used for the synthesis of antibody-drug conjugates (ADC). Man-GIcNAc-oxazoline is applicable for cancer research .
Target:
Research Areas:
BCN-endo-PEG2-maleimide is an ADC Linker containing 4 PEG units. BCN-endo-PEG2-maleimide contains the lyophilic bidentate macrocyclic ligand endo-BCN, which can further synthesize macrocyclic complexes. In click chemistry, endo-BCN can react with molecules containing azide groups to form stable triazoles in the absence of catalysts. Its maleimide group (-Maleimide) degrades in aqueous media and has been used in drug delivery studies.
Cat. No.: HY-172820
Synonyms: DP303c
Cat. No.: HY-179204S
CAS No.: 2911575-77-2
Cat. No.: HY-P992322
Target:
Research Areas:
BAY-79-4620 Antibody is a potent and selective CAIX antibody with a human CAIX Kd of 3.6 nM. BAY-79-4620 Antibody yields antibody-drug conjugate (ADC) through conjugating with Monomethyl auristatin E (HY-15162) via a self-immolative enzyme-cleavable linker. BAY-79-4620 Antibody can be used for the research of cervical carcinoma, non-small cell lung carcinoma, breast carcinoma, pancreatic carcinoma, gastric carcinoma, prostate carcinoma .
Cat. No.: HY-W800621
CAS No.: 2055024-59-2
Target:
Research Areas:
Fmoc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine for use in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
Cat. No.: HY-W800622
CAS No.: 2055024-58-1
Target:
Research Areas:
Fmoc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
Cat. No.: HY-W800623
CAS No.: 2055024-57-0
Target:
Research Areas:
Fmoc-PEG6-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Fmoc protecting group may be removed with piperidine to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
Cat. No.: HY-W800624
CAS No.: 2055024-55-8
Target:
Research Areas:
Boc-PEG2-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
Cat. No.: HY-W800625
CAS No.: 2055024-54-7
Target:
Research Areas:
Boc-PEG4-Val-Cit-PAB-OH is an enzyme-cleavable ADC linker featuring a Boc-protected amine, a hydrophilic PEG spacer, and a Val-Cit-PAB dipeptide. The benzylic alcohol on the PAB can be used to attach with reactive groups such as PNP for conjugation with drug payloads. The Boc protecting group may be removed with acid to reveal a primary amine which may be used in coupling reactions to form amides. The Val-Cit-PAB is cleaved by cellular proteases for efficient release of payloads to the cell.
Cat. No.: HY-145736
CAS No.: 2246363-68-6
Research Areas:
β-Glucuronide-dPBD-PEG5-NH2 is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD. β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 has antitumor activity .
Cat. No.: HY-145736A
CAS No.: 2246364-63-4
Research Areas:
β-Glucuronide-dPBD-PEG5-NH2 TFA is the β-glucuronide-linked pyrrolobenzodiazepine dimer, which binds to the prenylated antibody for synthesis of antibody-drug conjugate (ADC) cIRCR201-dPBD.β-glucuronide-linkage as a cleavable linker. β-Glucuronide-dPBD-PEG5-NH2 TFA, as a proagent of cIRCR201-dPBD, reduces side effects. β-Glucuronide-dPBD-PEG5-NH2 TFA can induce apoptosis and arrest cell cycle. β-Glucuronide-dPBD-PEG5-NH2 TFA has antitumor activity .
Cat. No.: HY-183594
CAS No.: 3037373-65-9
Target:
Research Areas:
Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal is a linker-payload conjugate. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal contains the linker D-2,4-DHB-NH2-AA(bPEG8)-Mal (HY-183595) and the cytotoxic agent Exatecan (HY-13631), a potent DNA topoisomerase I inhibitor. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal can be utilized for the development of antibody-drug conjugates (ADCs) .
Synonyms: BAY 1187982
Research Areas:
Cat. No.: HY-156514
CAS No.: 2987938-97-4
Target:
Research Areas:
MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research .
Cat. No.: HY-185428
Target:
Research Areas:
TRS-005 is an anti-CD20 ADC, formed by conjugating an anti-CD20 monoclonal antibody to MMAE (HY-15162) via a Val-Cit (HY-140014) linker. TRS-005 targets CD20-positive tumor cells and delivers MMAE into cells through receptor-mediated endocytosis. TRS-005 can be used for research on relapsed/refractory B-cell non-Hodgkin lymphoma (specifically diffuse large B-cell lymphoma) .
Cat. No.: HY-185561
Synonyms: RC88
Research Areas:
Misitatug blivedotin (RC88) is an antibody-drug conjugate (ADC) targeting mesothelin (MSLN). Misitatug blivedotin is formed by conjugating the humanized anti-mesothelin monoclonal antibody Misitatug (HY-P990929) with the microtubule inhibitor Monomethyl auristatin E (MMAE) (HY-15162) via a cleavable linker. Misitatug blivedotin binds to mesothelin and exhibits dose‐dependent antitumor activity. Misitatug blivedotin can be used for the research of ovarian cancer, non-squamous non-small-cell lung carcinoma, cervical cancer .
Cat. No.: HY-185718
Research Areas:
Trastuzumab-DM4 is an antibody-drug conjugate (ADC) formed by conjugating Trastuzumab (HY-P9907) with DM4 (sulfo-SPDB-DM4) (HY-101141) via a cleavable linker. DM4 is a tubulin inhibitor that suppresses cell division. Trastuzumab-DM4 significantly inhibits tumor growth in Trastuzumab-resistant HER2 xenograft tumor models. Trastuzumab-DM4 can be used for the research of HER2-positive breast cancer .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
